Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
153.80
+5.24 (+3.53%)
Streaming Delayed Price
Updated: 3:17 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Week In Review: BeiGene Raises $3.5 Billion In Shanghai STAR Board IPO
December 04, 2021
Beijing's BeiGene announced its Shanghai STAR Exchange IPO will raise $3.5 billion in gross proceeds for the company, more than the predictions of $3 billion. It is the third listing for the company,...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
BeiGene - EUSA Pharma's Siltuximab Approved In China For Multicentric Castleman Disease
December 03, 2021
The China National Medical Products Administration has approved BeiGene Ltd (NASDAQ: BGNE) / EUSA Pharma (UK) Ltd's Sylvant (siltuximab) for adult...
Via
Benzinga
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
December 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases...
Via
Benzinga
Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal
November 27, 2021
In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to...
Via
Talk Markets
Why BeiGene Shares Are Rising
September 17, 2021
Beigene Ltd (NASDAQ: BGNE) shares are trading higher by 3.8% at $400 after the company announced it received a positive CHMP opinion for BRUKINSA for the treatment of adults...
Via
Benzinga
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
November 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
BeiGene's Brukinsa Approved In Europe For Rare Type Of Blood Cancer
November 24, 2021
The European Commission has approved BeiGene Ltd's (NASDAQ: BGNE) BRUKINSA (zanubrutinib) for Waldenström's macroglobulinemia (WM). WM is a type of...
Via
Benzinga
Week In Review: BeiGene Cleared To Stage $3 Billion IPO On Shanghai STAR Exchange
November 20, 2021
Beijing's BeiGene was approved to stage a $3 billion IPO on Shanghai’s STAR Exchange, the company's third listing. Previously, the company completed an $182 million IPO on the NASDAQ in 2016 and a $900...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Week In Review: Two China Affiliated Biopharmas Raise $585 Million In IPOs
November 06, 2021
LianBio raised $325 million in its Nasdaq IPO at a market capitalization of $1.9 billion to support its drug in-licensings for China. Beijing Clover Biopharma also completed a $260 million IPO in Hong...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Here's My Top Value Stock To Buy Right Now
November 01, 2021
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications.
Via
Talk Markets
Wednesday Market Coverage
October 20, 2021
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.
Via
Talk Markets
Week In Review: Hansoh Signs $456 Million Deal For siRNA Products
October 16, 2021
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
October 12, 2021
Upgrades For Callaway Golf Co (NYSE:ELY), Compass ...
Via
Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Exposures
Product Safety
This Potential Indication Could Be a Winner for Novartis
September 29, 2021
The U.S. Food and Drug Administration accepted Novartis' filing for tislelizumab to treat esophageal cancer.
Via
The Motley Fool
Exposures
Product Safety
Notable Beigene Insider Trades $3.11 Million In Company Stock
September 23, 2021
Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large buy and sell of company shares on September 20, according to a new SEC filing. What Happened: A Form 4 filing...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
48 Biggest Movers From Friday
September 20, 2021
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by...
Via
Benzinga
Why BeiGene's Shares Jumped on Friday
September 17, 2021
The Chinese pharmaceutical company is racking up approvals for its lead oncology drug, Brukinsa.
Via
The Motley Fool
Beigene Insider Trades $33.79 Million In Company Stock
September 17, 2021
John Oyler, Chief Executive Officer at Beigene (NASDAQ:BGNE), made a large insider sell on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U....
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 17, 2021
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 53.98% to $3.48 during Friday's pre-market session. The company's market cap stands at $147.6...
Via
Benzinga
15 Stocks Moving in Friday's Pre-Market Session
September 17, 2021
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ABCL) rose 18% to $23.35 in pre-market trading....
Via
Benzinga
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
September 16, 2021
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-...
Via
Benzinga
Notable Beigene Insider Makes $4.62 Million Sale
September 16, 2021
Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large insider sell on September 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S....
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
September 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
Leap Therapeutics Stock Is Moving Higher On Updated DKN-01 Combo Trial Data In Gastric Cancer
September 16, 2021
Leap Therapeutics Inc (NASDAQ: LPTX) announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with ...
Via
Benzinga
BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
September 15, 2021
The FDA has granted accelerated approval to BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for relapsed or refractory (R/R) marginal zone lymphoma (...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
September 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
Exposures
COVID-19
3 Stocks Insiders Are Buying
September 14, 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...
Via
Benzinga
Why Are Leap Therapeutics Shares Trading Higher On Monday?
September 13, 2021
Leap Therapeutics Inc (NASDAQ: LPTX) stock increased over 30% premarket as the investors are responding positively ahead of the Company’s presentation of new data...
Via
Benzinga
Why BeiGene Stock Is Soaring This Week
September 02, 2021
The company won another FDA approval for blood cancer drug Brukinsa.
Via
The Motley Fool
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.